Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 6.22 percent. This is a 10.87 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $1.115 million which beat the analyst consensus estimate of $750.000 thousand by 48.67 percent.